VANCOUVER, British Columbia, Dec. 17, 2025 (GLOBE NEWSWIRE) — Yukon Metals Corp. (CSE: YMC, FSE: E770, OTCQB: YMMCF) (“Yukon Metals” or the “Company”) announces that the Board of Directors of the Company (the “”Board”) has appointed Jim Coates (Executive Vice President and a Director of the Company) as Interim Chief Executive Officer of the Company effective immediately. Mr. Coates replaces Rory Quinn who has made the decision to resign as President, Chief Executive Officer and a Director of the Company. The Board will initiate a search for a successor Chief Executive Officer and will work with management and an executive search firm to ensure success in the process. Pat Burke, Chair of the Board of Directors said, “We want to thank Rory for his work and efforts launching Yukon Metals into its current position as a company and...

Amsterdam, December 17, 2025 SBM Offshore announces it has signed a contract extension related to the lease and operation of FPSOs Mondo and Saxi Batuque with Esso Exploration Angola (Block 15) Limited, as the Operator of Block 15, an affiliate of ExxonMobil. The extension secures ownership and operations by SBM Offshore until 2032. The agreement includes life-extension activities, for equipment replacement and refurbishment, to maintain high safety standards and ensure operational excellence throughout the contract term. The scope of work is expected to start in 2026. The extension of the contract marks a recognition of SBM Offshore’s capability to manage complex offshore brownfield work as well as its capabilities in the operation and maintenance of deepwater assets. Through these contracts, SBM Offshore supports Block 15 Contractor...

Gated townhome community offers modern designs and a central location in Las Vegas LAS VEGAS, Dec. 17, 2025 (GLOBE NEWSWIRE) — StoryBook Homes, a Las Vegas-based homebuilder, today announced the opening of its newest gated townhome community, Parkhill Crest in Las Vegas. Located less than 15 minutes from Nellis Air Force Base and downtown Las Vegas, the gated community features a collection of three spacious townhome designs priced from the mid-$300,000s. Parkhill Crest offers two-story townhomes ranging from 1,727 to 1,888 square feet, with attached two-car garages, up to four bedrooms and two and a half baths. The community features modern home designs, versatile loft spaces, ample storage spaces, and open floor plans to fit every lifestyle. For home shoppers needing to move soon, quick move-in and move-in ready homes with Designer...

Exclusive community of luxury homes on one-acre home sites now showcases professionally designed model home available for tours LEANDER, Texas, Dec. 17, 2025 (GLOBE NEWSWIRE) — Toll Brothers, Inc. (NYSE:TOL), the nation’s leading builder of luxury homes, today announced its newest Austin-area model home is now open at Toll Brothers at Woodland Estates, a single-family home community in Leander, Texas. The highly anticipated and professionally designed Bell Springs model home showcases the exceptional architecture, luxurious finishes, and personalization opportunities available in this premier community. The new model home is now available for tours at 2321 Greatwood Trail in Leander. Nestled in the scenic Texas Hill Country, Toll Brothers at Woodland Estates features spacious one-acre home sites and a collection of thoughtfully...

No Shareholder Action Required at This Time BETHLEHEM, Pa., Dec. 17, 2025 (GLOBE NEWSWIRE) — OraSure Technologies, Inc. (“OraSure” and “OTI”) (NASDAQ: OSUR), a leader in point-of-need and home diagnostic tests and sample management solutions, today confirmed that Altai Capital (“Altai”) has notified the Company of its intent to nominate two candidates, including the fund’s founder, Rishi Bajaj, to stand for election to the Company’s Board of Directors (the “Board”) at its 2026 Annual Meeting of Stockholders. The Company issued the following statement: The OraSure Board and management team are committed to moving the Company forward with a clear focus on shareholder value creation. We maintain open and constructive dialogue with our shareholders, and members of OraSure’s Board have engaged extensively with Altai Capital in recent...

        Company Announcement No 68/2025Peberlyk 46200 AabenraaDenmark Tel +45 74 37 37 37Fax +45 74 37 35 36 AL Sydbank A/SCVR No DK 12626509, Aabenraasydbank.dk17 December 2025  Dear Sirs Major shareholder announcement – Fagligt Fælles Forbund With reference to section 30, cf. section 38, of the Danish Capital Markets Act this is to announce that on 17 December 2025 AL Sydbank was informed that, as at 12 December 2025, the direct holdings of Fagligt Fælles Forbund, 31378028, Kampmannsgade 4, 1604 København V. represent 12.61% of the voting rights and 12.61% of the share capital of AL Sydbank A/S. Kind regards AL Sydbank A/SAttachmentSM 68 UK

                                                                   Press release – Paris, December 17, 2025, at 7:00 PM CET Danone SA announces the purchase of c.5.8 million of its own shares held by its Spanish subsidiary, with no impact on total Danone shares held by the GroupAs part of the simplification of its corporate structure, Danone SA purchased on December 17, 2025, all 5,780,005 of its own shares previously held by its Spanish subsidiary, Danone Spain. This transaction has no impact on the total Danone shares held by the Group. These shares, purchased at a price equal to the closing stock price as of December 17, 2025 (i.e. €77.46), have been allocated to employee shareholding plans. This transaction was implemented in the framework of the authorization granted by the Shareholders’ Meeting of April 24, 2025. About Danone...

Strasbourg (France), December 17, 2025, 17:45 p.m. CET – Transgene (Euronext Paris: TNG), a biotech company that designs and develops virus-based immunotherapies for the treatment of cancer, today announced that its management team will meet institutional investors during the upcoming editions of:LifeSci Partners Corporate Access Event (by LifeSci Partners), on January 12 and 13, 2026, in San Francisco (United States) in conjunction with the JP Morgan Healthcare Conference; Biomed Forum (by Allinvest Securities), on January 29, 2026, in Paris (France).*** ContactsTransgene:  Media: Investors & Analysts:Caroline Tosch Lucie LarguierCorporate and Scientific Communications Manager Chief Financial Officer (CFO)+33 (0)3 68 33 27 38 Nadege Bartolicommunication@transgene.fr Investor Relations Analystand Financial Communications...

Press release                                                                  Regulated information Brussels, December 17, 2025, 5.45pm CET Solvay today publishes its 2026 financial calendar.Event DateInterim dividend: ex-date January 19, 2026Interim dividend: payment date January 21, 2026Fourth quarter and full year 2025 earnings  February 24, 2026First quarter 2026 earnings  May 7, 2026Ordinary General Shareholders’ Meeting May 12, 2026Second quarter and first half year 2026 earnings  July 29, 2026Third quarter and first nine months 2026 earnings  November 4, 2026Quiet period dates will be provided prior to each earnings’ season.We invite you to join our mailing list to receive events notifications. More information can be found on www.solvay.com/en/investors Contacts Investor relations Geoffroy d’Oultremont:...

On track for initial clinical data in mid-2026 Marks a pivotal step toward scalable, accessible, off-the-shelf cell therapies for solid tumoursOslo, Norway, 17 December 2025 – Zelluna (OSE: ZLNA), a company pioneering allogeneic off-the-shelf cell therapies for cancer, today announced the submission of its Clinical Trial Application (CTA) to the UK Medicines and Healthcare products Regulatory Agency (MHRA) for ZI-MA4-1, the Company’s lead candidate. The CTA submission marks Zelluna’s transition from preclinical to clinical development and represents the successful delivery of all key milestones communicated for 2025:Manufacturing process locked (April 2025) Preclinical data package completed and key data published (December 2025) GMP clinical batch produced and quality-tested (December 2025) Clinical Trial Application submitted to...